GB201720975D0 - Anti-alpha synuclein antibodies - Google Patents
Anti-alpha synuclein antibodiesInfo
- Publication number
- GB201720975D0 GB201720975D0 GBGB1720975.0A GB201720975A GB201720975D0 GB 201720975 D0 GB201720975 D0 GB 201720975D0 GB 201720975 A GB201720975 A GB 201720975A GB 201720975 D0 GB201720975 D0 GB 201720975D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- alpha synuclein
- synuclein antibodies
- antibodies
- alpha
- synuclein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (33)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720975.0A GB201720975D0 (en) | 2017-12-15 | 2017-12-15 | Anti-alpha synuclein antibodies |
| KR1020207019487A KR102789446B1 (ko) | 2017-12-15 | 2018-12-13 | 항-알파 시누클레인 항체 |
| JP2020532596A JP7292279B2 (ja) | 2017-12-15 | 2018-12-13 | 抗αシヌクレイン抗体 |
| US16/771,993 US11261242B2 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
| MX2020005691A MX2020005691A (es) | 2017-12-15 | 2018-12-13 | Anticuerpos anti alfa-sinucleina. |
| MA051135A MA51135A (fr) | 2017-12-15 | 2018-12-13 | Anticorps anti-alpha-synucléine |
| EP18829767.5A EP3724224A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
| PE2020000707A PE20201061A1 (es) | 2017-12-15 | 2018-12-13 | Anticuerpos anti alfa-sinucleina |
| AU2018382530A AU2018382530B2 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
| MYPI2020002453A MY205948A (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
| TNP/2020/000069A TN2020000069A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
| SG11202004502SA SG11202004502SA (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
| CN201880080854.1A CN111479826B (zh) | 2017-12-15 | 2018-12-13 | 抗α突触核蛋白抗体 |
| TNP/2021/000169A TN2021000169A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
| BR112020010504-0A BR112020010504A2 (pt) | 2017-12-15 | 2018-12-13 | anticorpos anti-alfa-sinucleína |
| EA202091478A EA202091478A1 (ru) | 2017-12-15 | 2018-12-13 | Антитела |
| RU2020123274A RU2787039C2 (ru) | 2017-12-15 | 2018-12-13 | Антитела против альфа-синуклеина |
| PCT/EP2018/084697 WO2019115674A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
| CA3083199A CA3083199A1 (en) | 2017-12-15 | 2018-12-13 | Anti-alpha-synuclein antibodies |
| UAA202002941A UA126295C2 (uk) | 2017-12-15 | 2018-12-13 | Антитіло до альфа-синуклеїну |
| TW112114559A TW202332692A (zh) | 2017-12-15 | 2018-12-14 | 抗體 |
| UY0001038010A UY38010A (es) | 2017-12-15 | 2018-12-14 | Anticuerpos de alfa-sinucleína y sus usos |
| ARP180103657A AR115192A1 (es) | 2017-12-15 | 2018-12-14 | Anticuerpos |
| TW107145283A TWI801469B (zh) | 2017-12-15 | 2018-12-14 | 抗體 |
| IL275187A IL275187B1 (en) | 2017-12-15 | 2020-06-07 | Anti-alpha-synuclein antibodies |
| ZA2020/03542A ZA202003542B (en) | 2017-12-15 | 2020-06-12 | Anti-alpha-synuclein antibodies |
| PH12020551007A PH12020551007A1 (en) | 2017-12-15 | 2020-06-14 | Anti-alpha-synuclein antibodies |
| CL2020001605A CL2020001605A1 (es) | 2017-12-15 | 2020-06-15 | Anticuerpos anti alfa-sinucleína. |
| MX2024013356A MX2024013356A (es) | 2017-12-15 | 2020-07-13 | Anticuerpos anti alfa-sinucleina |
| ECSENADI202039623A ECSP20039623A (es) | 2017-12-15 | 2020-07-14 | Anticuerpos anti alfa-sinucleína |
| ZA2021/03456A ZA202103456B (en) | 2017-12-15 | 2021-05-21 | Anti-alpha-synuclein antibodies |
| US17/585,174 US12545720B2 (en) | 2017-12-15 | 2022-01-26 | Anti-alpha-synuclein antibodies |
| JP2023092397A JP7627300B2 (ja) | 2017-12-15 | 2023-06-05 | 抗αシヌクレイン抗体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720975.0A GB201720975D0 (en) | 2017-12-15 | 2017-12-15 | Anti-alpha synuclein antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201720975D0 true GB201720975D0 (en) | 2018-01-31 |
Family
ID=61009086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1720975.0A Ceased GB201720975D0 (en) | 2017-12-15 | 2017-12-15 | Anti-alpha synuclein antibodies |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11261242B2 (https=) |
| EP (1) | EP3724224A1 (https=) |
| JP (2) | JP7292279B2 (https=) |
| KR (1) | KR102789446B1 (https=) |
| CN (1) | CN111479826B (https=) |
| AR (1) | AR115192A1 (https=) |
| AU (1) | AU2018382530B2 (https=) |
| BR (1) | BR112020010504A2 (https=) |
| CA (1) | CA3083199A1 (https=) |
| CL (1) | CL2020001605A1 (https=) |
| EA (1) | EA202091478A1 (https=) |
| EC (1) | ECSP20039623A (https=) |
| GB (1) | GB201720975D0 (https=) |
| IL (1) | IL275187B1 (https=) |
| MA (1) | MA51135A (https=) |
| MX (2) | MX2020005691A (https=) |
| MY (1) | MY205948A (https=) |
| PE (1) | PE20201061A1 (https=) |
| PH (1) | PH12020551007A1 (https=) |
| SG (1) | SG11202004502SA (https=) |
| TN (2) | TN2020000069A1 (https=) |
| TW (2) | TW202332692A (https=) |
| UA (1) | UA126295C2 (https=) |
| UY (1) | UY38010A (https=) |
| WO (1) | WO2019115674A1 (https=) |
| ZA (2) | ZA202003542B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| WO2020079113A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
| US20230074436A1 (en) * | 2019-09-20 | 2023-03-09 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| WO2021113464A1 (en) * | 2019-12-04 | 2021-06-10 | Friedman Simon | Protein blocking assembly and methods of making and using |
| KR20240176098A (ko) * | 2023-06-14 | 2024-12-24 | 경상국립대학교산학협력단 | 알파 시누클레인 에피토프를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU2002221132A1 (en) | 2000-12-13 | 2002-07-01 | Taisho Pharmaceutical Co. Ltd. | Novel antibody |
| US7479482B2 (en) | 2001-11-21 | 2009-01-20 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| SI1633189T1 (sl) | 2003-05-19 | 2017-12-29 | Prothena Biosciences Limited | Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| HUE025225T2 (en) * | 2007-02-23 | 2016-02-29 | Prothena Biosciences Ltd | Prevention and treatment of synucleinopathic and amyloidogenic diseases |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| AU2009328505B2 (en) | 2008-12-19 | 2014-11-27 | Panima Pharmaceuticals Ag | Human anti-alpha-synuclein autoantibodies |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CA2789963C (en) * | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| US9116157B2 (en) | 2010-11-05 | 2015-08-25 | Brandeis University | Ice-cleaved alpha-synuclein as a biomarker |
| DE102011008153B4 (de) | 2011-01-08 | 2018-08-09 | Aj Roboscreen Gmbh | Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein |
| HUE041391T2 (hu) * | 2011-06-23 | 2019-05-28 | Biogen Int Neuroscience Gmbh | Anti-alfa-szinukleinkötõ molekulák |
| US8609820B2 (en) * | 2011-10-28 | 2013-12-17 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| NZ629296A (en) | 2012-01-27 | 2016-06-24 | Prothena Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| US12156912B2 (en) | 2012-05-18 | 2024-12-03 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| EP2857419B1 (en) | 2012-05-30 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US10035847B2 (en) | 2013-10-02 | 2018-07-31 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| EP3071974A2 (en) | 2013-11-19 | 2016-09-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
| CA2924268C (en) | 2013-11-21 | 2021-05-18 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
| JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
| WO2015179867A1 (en) | 2014-05-23 | 2015-11-26 | University Of South Florida | Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| WO2016040903A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded amyloid beta protein |
| WO2016040905A1 (en) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded alpha synuclein protein |
| ES2953855T3 (es) | 2014-09-11 | 2023-11-16 | Univ Texas | Detección de proteínas mal plegadas |
| US9732148B2 (en) | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| JP6989927B2 (ja) | 2015-08-25 | 2022-02-03 | プロセナ バイオサイエンシーズ リミテッド | リン酸化アルファ－シヌクレインを検出するための方法 |
| US10639383B2 (en) | 2015-11-23 | 2020-05-05 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
| WO2017176835A2 (en) | 2016-04-06 | 2017-10-12 | Imago Pharmaceuticals, Inc. | Therapeutic antibodies for treatment of neurodegeneration |
| CN109475616B (zh) | 2016-06-02 | 2022-10-18 | 麦迪穆有限责任公司 | 针对α-突触核蛋白的抗体及其用途 |
| GB201611840D0 (en) | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
| US20190194324A1 (en) | 2016-08-23 | 2019-06-27 | The Johns Hopkins University | THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR |
| AR110074A1 (es) | 2016-11-15 | 2019-02-20 | H Lundbeck As | Agentes, usos y métodos para el tratamiento de la sinucleinopatía |
| US20180134775A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (7A11) |
| US20180134776A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (4H6) |
| US20180134777A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (11D12) |
| EP3551228A4 (en) | 2016-12-12 | 2020-08-12 | The Michael J. Fox Foundation For Parkinson's Research | ANTIBODIES FOR HUMAN ALPHA SYNUCLEIN |
| CN110072888B (zh) | 2016-12-16 | 2023-07-18 | H.隆德贝克有限公司 | 药剂、用途和方法 |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| CA3049110A1 (en) | 2017-01-06 | 2018-07-12 | Abl Bio Inc. | Anti-.alpha.-syn antibody and use thereof |
| JP2020504151A (ja) | 2017-01-09 | 2020-02-06 | カリフォルニア インスティチュート オブ テクノロジー | パーキンソン病の診断および治療薬における腸内微生物叢の使用 |
| CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| JOP20190227A1 (ar) | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
| TW201901153A (zh) | 2017-05-16 | 2019-01-01 | 美商安培恩股份有限公司 | 折疊錯誤之ｔａｕ蛋白的檢測及檢測折疊錯誤之ｔａｕ蛋白的套組 |
| WO2018237338A1 (en) | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
-
2017
- 2017-12-15 GB GBGB1720975.0A patent/GB201720975D0/en not_active Ceased
-
2018
- 2018-12-13 EP EP18829767.5A patent/EP3724224A1/en active Pending
- 2018-12-13 UA UAA202002941A patent/UA126295C2/uk unknown
- 2018-12-13 SG SG11202004502SA patent/SG11202004502SA/en unknown
- 2018-12-13 MY MYPI2020002453A patent/MY205948A/en unknown
- 2018-12-13 AU AU2018382530A patent/AU2018382530B2/en active Active
- 2018-12-13 TN TNP/2020/000069A patent/TN2020000069A1/en unknown
- 2018-12-13 EA EA202091478A patent/EA202091478A1/ru unknown
- 2018-12-13 MA MA051135A patent/MA51135A/fr unknown
- 2018-12-13 BR BR112020010504-0A patent/BR112020010504A2/pt unknown
- 2018-12-13 PE PE2020000707A patent/PE20201061A1/es unknown
- 2018-12-13 US US16/771,993 patent/US11261242B2/en active Active
- 2018-12-13 WO PCT/EP2018/084697 patent/WO2019115674A1/en not_active Ceased
- 2018-12-13 KR KR1020207019487A patent/KR102789446B1/ko active Active
- 2018-12-13 JP JP2020532596A patent/JP7292279B2/ja active Active
- 2018-12-13 MX MX2020005691A patent/MX2020005691A/es unknown
- 2018-12-13 CA CA3083199A patent/CA3083199A1/en active Pending
- 2018-12-13 TN TNP/2021/000169A patent/TN2021000169A1/en unknown
- 2018-12-13 CN CN201880080854.1A patent/CN111479826B/zh active Active
- 2018-12-14 UY UY0001038010A patent/UY38010A/es not_active Application Discontinuation
- 2018-12-14 TW TW112114559A patent/TW202332692A/zh unknown
- 2018-12-14 TW TW107145283A patent/TWI801469B/zh active
- 2018-12-14 AR ARP180103657A patent/AR115192A1/es unknown
-
2020
- 2020-06-07 IL IL275187A patent/IL275187B1/en unknown
- 2020-06-12 ZA ZA2020/03542A patent/ZA202003542B/en unknown
- 2020-06-14 PH PH12020551007A patent/PH12020551007A1/en unknown
- 2020-06-15 CL CL2020001605A patent/CL2020001605A1/es unknown
- 2020-07-13 MX MX2024013356A patent/MX2024013356A/es unknown
- 2020-07-14 EC ECSENADI202039623A patent/ECSP20039623A/es unknown
-
2021
- 2021-05-21 ZA ZA2021/03456A patent/ZA202103456B/en unknown
-
2022
- 2022-01-26 US US17/585,174 patent/US12545720B2/en active Active
-
2023
- 2023-06-05 JP JP2023092397A patent/JP7627300B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280780A (en) | Anti-TIGIT antibodies | |
| IL268517A (en) | Anti-tigit antibodies | |
| IL280013A (en) | Anti-IL36R antibodies | |
| PT3625259T (pt) | Anticorpos anti-sirpalfa | |
| IL279352A (en) | IL-11RA antibodies | |
| ZA202106370B (en) | Anti-alpha synuclein antibodies | |
| GB201709808D0 (en) | Antibodies | |
| IL278010A (en) | Antibodies to galectin 10 | |
| SG10201914130VA (en) | GARP-TGF-β ANTIBODIES | |
| SG11202106171WA (en) | Anti-btla antibodies | |
| IL277030A (en) | Antibodies | |
| GB201720975D0 (en) | Anti-alpha synuclein antibodies | |
| IL271067A (en) | Anti-trkb antibodies | |
| SG11202102114UA (en) | Anti-klrg1 antibodies | |
| GB201806084D0 (en) | Antibodies | |
| GB201720978D0 (en) | Anti-alpha synuclein antibodies | |
| GB201711785D0 (en) | Antibodies | |
| SG11202105718TA (en) | Modified antibodies | |
| GB201819952D0 (en) | Antibodies | |
| GB201817313D0 (en) | Antibodies | |
| GB201817312D0 (en) | Antibodies | |
| GB201817311D0 (en) | Antibodies | |
| GB201817309D0 (en) | Antibodies | |
| GB201806099D0 (en) | Galectin-10 Antibodies | |
| GB201717006D0 (en) | Anti-OPG antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |